Detailed mechanistic analysis of gevokizumab, an allosteric anti-il-1b antibody with differential receptor-modulating propertiess

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 1, 2014, Pages 202-215

  Issafras, Hassan ^a   Corbin, John A ^a   Goldfine, Ira D ^a   Roell, Marina K ^a  

^a XOMA (US) LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEVOKIZUMAB; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING KINETICS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANTIBODIES, MONOCLONAL, HUMANIZED; HELA CELLS; HUMANS; INTERLEUKIN-1BETA; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-1;

EID: 84891637901     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205443     Document Type: Article

References (45)

1. Abdiche YN, Lindquist KC, Pinkerton A, Pons J, and Rajpal A (2011) Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis. Anal Biochem 411:139-151.
2. Arend WP, Malyak M, Guthridge CJ, and Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27-55.
3. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14:48-58.
4. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, Michelson K, Hunter JJ, and Kantak SS (2011) Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 216:313-320.
5. Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, and Nar H (2013) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1b. J Mol Biol 425:94-111.
6. Bourke E, Cassetti A, Villa A, Fadlon E, Colotta F, and Mantovani A (2003) IL-1 beta scavenging by the type II IL-1 decoy receptor in human neutrophils. J Immunol 170:5999-6005.
7. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, and Myszka DG (2006) Exploring one-shot kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 358:281-288.
8. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
9. Church LD and McDermott MF (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 11:81-89.
10. Cohen SB, Proudman S, Kivitz AJ, Burch FX, Donohue JP, Burstein D, Sun YN, Banfield C, Vincent MS, and Ni L, et al. (2011) A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 13:R125.
11. Colquhoun D (2007) Why the Schild method is better than Schild realised. Trends Pharmacol Sci 28:608-614.
12. Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. FASEB J 8: 1314-1325.
13. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
14. Dinarello CA (2005) The many worlds of reducing interleukin-1. Arthritis Rheum 52: 1960-1967.
15. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720-3732.
16. Evans RJ, Bray J, Childs JD, Vigers GPA, Brandhuber BJ, Skalicky JJ, Thompson RC, and Eisenberg SP (1995) Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 b by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 b. J Biol Chem 270:11477-11483.
17. Fredericks ZL, Forte C, Capuano IV, Zhou H, Vanden Bos T, and Carter P (2004) Identification of potent human anti-IL-1RI antagonist antibodies. Protein Eng Des Sel 17:95-106.
18. Furst DE (2004) Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26:1960-1975.
19. Gaddum JH (1957) Theories of drug antagonism. Pharmacol Rev 9:211-218.
20. Glaser RW (1993) Antigen-antibody binding and mass transport by convection and diffusion to a surface: a two-dimensional computer model of binding and dissociation kinetics. Anal Biochem 213:152-161.
21. Gregory KJ, Sexton PM, and Christopoulos A (2007) Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 5:157-167.
22. Grütter MG, van Oostrum J, Priestle JP, Edelmann E, Joss U, Feige U, Vosbeck K, and Schmitz A (1994) A mutational analysis of receptor binding sites of interleukin-1 beta: differences in binding of human interleukin-1 beta muteins to human and mouse receptors. Protein Eng 7:663-671.
23. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, and Solinger A (2012) Interleukin-1b-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 71:563-566.
24. Hawkins PN, Lachmann HJ, Aganna E, and McDermott MF (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50:607-612.
25. Kenakin TP (2009) A pharmacology primer: theory, applications, and methods, Academic Press/Elsevier, Amsterdam, Boston.
26. Kortt AA, Nice E, and Gruen LC (1999) Analysis of the binding of the Fab fragment of monoclonal antibody NC10 to influenza virus N9 neuraminidase from tern and whale using the BIAcore biosensor: effect of immobilization level and flow rate on kinetic analysis. Anal Biochem 273:133-141.
27. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, and Hawkins PN; Canakinumab in CAPS Study Group (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416-2425.
28. Liu C, Hart RP, Liu XJ, Clevenger W, Maki RA, and De Souza EB (1996) Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem 271:20965-20972.
29. Lovell DJ, Bowyer SL, and Solinger AM (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52:1283-1286.
30. Mantovani A, Locati M, Vecchi A, Sozzani S, and Allavena P (2001) Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 22:328-336.
31. McDermott MF (2009) Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today (Barc) 45:423-430.
32. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin CE, Wignall JM, Jenkins NA, and Brannan CI, et al. (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10:2821-2832.
33. Myszka DG, He X, Dembo M, Morton TA, and Goldstein B (1998) Extending the range of rate constants available from BIACORE: interpreting mass transportinfluenced binding data. Biophys J 75:583-594.
34. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, Handa M, Horwitz AH, Roell MK, and Haak-Frendscho M, et al. (2011) XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1b-mediated diseases. MAbs 3:49-60.
35. Pascual V, Allantaz F, Arce E, Punaro M, and Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479-1486.
36. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612.
37. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, and Bohmann DJ, et al. (2010) Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 285:20607-20614.
38. Simon A and van der Meer JW (2007) Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 292:R86-R98.
39. Smith DE, Hanna R, Della Friend, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, and Sims JE (2003) The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18:87-96.
40. Symons JA, Young PR, and Duff GW (1995) Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 92:1714-1718.
41. Valtiner M, Donaldson SH, Jr, Gebbie MA, and Israelachvili JN (2012) Hydrophobic forces, electrostatic steering, and acid-base bridging between atomically smooth self-assembled monolayers and end-functionalized PEGolated lipid bilayers. J Am Chem Soc 134:1746-1753.
42. Vigers GP, Anderson LJ, Caffes P, and Brandhuber BJ (1997) Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 386:190-194.
43. Wang D, Zhang S, Li L, Liu X, Mei K, and Wang X (2010) Structural insights into the assembly and activation of IL-1b with its receptors. Nat Immunol 11:905-911.
44. Weber A, Wasiliew P, and Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3:cm1.
45. Wyman J and Gill SJ (1990) Binding and Linkage: Functional Chemistry of Biological Macromolecules, University Science Books, Mill Valley, C.A.